SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
(HealthDay News) – ROR2 gene mutations are expressed in a subset of soft-tissue sarcomas, including leiomyosarcoma (LMS), gastrointestinal stromal tumors (GIST), and desmoid-type fibromatosis (DTF), ...
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
The ROR family of proteins includes ROR1 and ROR2 – receptor tyrosine kinases. ROR1 is especially interesting to pharmacologists as it has only been observed in cancerous and embryonic cells, and ...
Biologists discovered that a mutation in the ROR2 gene is linked to beak size reduction in numerous breeds of domestic pigeons. Surprisingly, different mutations in ROR2 also underlie a human disorder ...
Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results